Literature DB >> 34223937

[Hidradenitis suppurativa/acne inversa in daily practice].

H Kurzen1,2, K Fritz3,4, A Altenburg5,6.   

Abstract

Hidradenitis suppurativa (HS) is a chronic inflammatory disease, characterized by abscess formation and mutilating scar formation in the body folds. The burden of disease is high for both patient and treating physician. In dermatological daily practice, proper patient education and formation of a trustful physician-patient relationship are of highest importance. HS patients are treated both conservatively and surgically mostly by dermatologists, which requires extensive knowledge of the pathogenesis, trigger factors, comorbidities and treatment options. Interdisciplinary collaboration with other disciplines is still underdeveloped. New physical treatments (laser, radiofrequency, intense pulsed light [IPL]), topical and systemic therapies enable good ambulatory long-term management for all HS stages.
© 2021. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Ambulatory care; Lasers; Long-term management; Suffering; Surgical procedures

Year:  2021        PMID: 34223937     DOI: 10.1007/s00105-021-04850-0

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  2 in total

1.  Laser-Haarentfernung verändert den Krankheitsverlauf bei leichter Hidradenitis suppurativa.

Authors:  Allard R J V Vossen; Hessel H van der Zee; Marinka Terian; Martijn B A van Doorn; Errol P Prens
Journal:  J Dtsch Dermatol Ges       Date:  2018-07       Impact factor: 5.584

2.  Assessing the psychological burden of patients with hidradenitis suppurativa.

Authors:  Verena G Frings; Boris Bauer; Manuel Glöditzsch; Matthias Goebeler; Dagmar Presser
Journal:  Eur J Dermatol       Date:  2019-06-01       Impact factor: 3.328

  2 in total
  1 in total

1.  [Hidradenitis suppurativa/acne inversa: From "orphan disease" to a curable inflammatory skin disorder].

Authors:  Christos C Zouboulis; E von Stebut
Journal:  Hautarzt       Date:  2021-07-29       Impact factor: 0.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.